Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Cancer and Hematology Center
Developmental Therapeutics Phase I Clinic
Liver Tumor Program
Neuroblastoma Program
Soft Tissue Sarcoma Program
Solid Tumor Programs
Texas Medical Center
Address
6701 Fannin St., Ste. 1510.00
Houston, TX 77030
Jennifer H. Foster, MD, MPH
Director, Solid Tumor Programs
Clinical Director, Neuroblastoma Program
Assistant Director, Developmental Therapeutics Program
Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
Education
School | Education | Degree | Year |
---|---|---|---|
Baylor College of Medicine | Fellowship | Clinical Fellow, Pharmacology | 2015 |
Baylor College of Medicine | Fellowship | Pediatric Hematology/Oncology | 2013 |
University of Washington School of Medicine | Residency | Pediatrics | 2010 |
University of Washington School of Medicine | Internship | Pediatrics | 2009 |
University of Hawaii School of Medicine | Medical School | Doctor of Medicine | 2007 |
San Diego State University | Masters | Masters in Public Health | 2003 |
University of Notre Dame | Bachelors | Bachelor of Arts, Mandarin Chinese | 2001 |
About
Dr. Jennifer Foster is a pediatric oncologist at Baylor College of Medicine/Texas Children’s Cancer and Hematology Center with clinical and research expertise in pediatric solid tumors and clinical pharmacology. She serves as Director of the Solid Tumor Programs, Clinical Director of the Neuroblastoma Program, and Assistant Director of the Developmental Therapeutics Program at Texas Children’s Cancer Center, one of the largest pediatric cancer center in the United States.
Her clinical and research interests are to bring novel therapies into early phase clinical trials for patients with neuroblastoma and other solid tumors, as well as to mitigate toxicities of therapy. As such, she is dual board certified in Pediatric Hematology-Oncology and Clinical Pharmacology. She has expertise in moving novel agents from the pre-clinical arena to the implementation of early phase clinical trials. She successfully completed the pre-clinical evaluation for the first-in-class NEDD8 activating enzyme inhibitor pevonedistat and partnered with Takeda to develop and conduct the Phase 1 clinical trial through the Children’s Oncology Group (COG).
As the site Principal Investigator for the National Cancer Institute’s Pediatric Early Phase Clinical Trials Network, she is responsible for the implementation and conduct of these trials at our institution, and is actively investigating novel agents through our Developmental Therapeutics pre-clinical program with the goal of incorporating them into future clinical trials.
Board Certifications
American Board of Pediatrics
American Board of Pediatrics - Pediatric Hematology/Oncology
American Board of Clinical Pharmacology - Clinical Pharmacology
Organizations
Organization Name | Role |
---|---|
American Academy of Pediatrics (AAP) | Member |
American Medical Association (AMA) | Member |
American Society of Pediatric Hematology/Oncology (ASPHO) | Member |
Selected Publications
Awards & Honors
2022 Dr. Peter Adamson Young Investigator Award, Children's Oncology Group (COG)
2020 Research Mentor Award, Texas Children's Hospital
2019 Faculty Award for Excellence in Patient Care, Baylor College of Medicine
2017 Awardee Rising Star in Translational Cancer Research, Society for Translational Oncology
2013 Alex’s Lemonade Stand Foundation, Research Scholar
Board Certification
Language
Latest Blogs
Latest Videos
Neuroblastoma Program at Texas Children’s Cancer Center®

MIBG Treatment at Texas Children’s Cancer Center

* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.